U
Ulthera
Biotech & Life Sciences · Mesa, United States · Founded 2004
Medical technology company developing non-invasive ultrasound-based devices for aesthetic medical procedures MoreLess
Ulthera, Inc. operates in the aesthetic medical device market, specializing in non-invasive skin lifting and tightening solutions. The company's flagship product, Ultherapy, utilizes ultrasound technology to stimulate collagen production, providing a non-surgical alternative for lifting the neck, chin, brow, and improving lines and wrinkles on the chest. Ulthera serves a diverse clientele, including dermatologists, plastic surgeons, and medical spas, targeting individuals seeking non-invasive cosmetic enhancements. The business model revolves around the sale of Ultherapy devices and consumables, as well as training and support services for medical professionals. Revenue is generated through direct sales, leasing options, and ongoing service agreements. Ulthera's market is characterized by a growing demand for non-surgical aesthetic treatments, driven by advancements in technology and increasing consumer preference for minimally invasive procedures.
Keywords: non-invasive, ultrasound therapy, skin lifting, collagen stimulation, aesthetic medical device, dermatologists, plastic surgeons, medical spas, cosmetic enhancements, FDA-cleared.
Company overview
Ulthera company information
The essential company record, classifications and operating signals in one place.
Valuation & funding
Ulthera funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jun 2014 | $600M | $600M | Merz | — |
| SERIES C✓Equity / VC | Feb 2011 | $11M | $42M | NEA · Apposite Capital | — |
| EARLY VC✓Equity / VC | May 2010 | $1.2M | $4.8M | Undisclosed | — |
| SERIES B✓Equity / VC | Jan 2008 | $23M | $90M | NEA · 3i Group | — |
| SERIES A✓Equity / VC | Dec 2005 | $5.5M | $22M | 3i Group | — |
Financials
Revenue over time
Available revenue history. Fields without reported data are omitted.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $82M | 0% |
| 2025 | $82M | 0% |
| 2024 | $82M | 0% |
| 2023 | $82M | 0% |
| 2022 | $82M | 0% |
| 2021 | $82M | 0% |
| 2020 | $82M | — |
Growth signals
Ulthera website traffic
Latest recorded traffic for Ulthera is 0 monthly website visits, down 100% over the last three months.
Comparisons
Ulthera compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Ulthera investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Ulthera's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Ulthera has talent and traffic
In the news
Latest news about Ulthera
Recent press, funding announcements, and product moves mentioning Ulthera — open to read from the original sources.
Market sentiment
What the market is saying about Ulthera
An AI-synthesized read of the highest-engagement posts about Ulthera on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ulthera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.












